Uplizna
Uplizna ingredients
| Active ingredient | Strength |
|---|---|
| Inebilizumab | 10 mg/mL |
What Uplizna is used for
The FDA lists the approved uses on the official label (below). In the EU, inebilizumab is approved as Uplizna for:
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Uplizna
- Generic name
- Inebilizumab
- Made by
- Horizon Therapeutics USA, Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- CD19-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA761142
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Inebilizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Uplizna?
Uplizna (Inebilizumab) is a cancer medicine made by Horizon Therapeutics USA, Inc., approved by the US FDA.
What are the ingredients of Uplizna?
Uplizna contains Inebilizumab (10 mg/mL).
Is Uplizna approved in Europe?
The same active substance is approved in the EU as Uplizna.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA